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Abstract
Objective
To determine the prevalence of neuromuscular junction (NMJ)
abnormalities in patients with mitochondrial disease.
Methods
Eighty patients with genetically proven mitochondrial disease were
recruited from a national center for mitochondrial disease in the
United Kingdom. Participants underwent detailed clinical and
neurophysiologic testing including single-fiber electromyography.
Results
The overall prevalence of neuromuscular transmission defects was
25.6%. The highest prevalence was in patients with pathogenic
dominant RRM2B variants (50%), but abnormalities were found in
a wide range of mitochondrial genotypes. The presence of NMJ
abnormalities was strongly associated with coexistent myopathy,
but not with neuropathy. Furthermore, 15% of patients with NMJ
abnormality had no evidence of either myopathy or neuropathy.
Conclusions
NMJ transmission defects are common in mitochondrial disease. In some patients, NMJ
dysfunction occurs in the absence of obvious pre- or post-synaptic pathology, suggesting that
the NMJ may be specifically affected.
Fatigue is one of the most common symptoms in patients with mitochondrial disease.1,2 A
cardinal feature of these disorders is multisystem involvement, and this fatigue may originate
in 1 or several locations in the brain, spinal cord, peripheral nerve, and skeletal muscle.3,4
A prime candidate is the neuromuscular junction (NMJ). There are striking similarities
between patients with some forms of mitochondrial disease and myasthenia gravis. Ptosis,
ophthalmoplegia, and proximal muscle weakness are commonly described in both conditions,
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and several articles have described the difficulty of dis-
tinguishing between them on clinical grounds alone.5–7 The
picture is further complicated by reports of abnormal neu-
rophysiologic indices of NMJ dysfunction in patients with
mitochondrial disease.8–10 However, these have been case
reports or small series in patients in whom a diagnosis of
mitochondrial disease was not always genetically proven.
Furthermore, no attempt has been made to investigate the
mechanism of the observed NMJ abnormalities. The prev-
alence of NMJ abnormalities in mitochondrial disease
remains unclear, and it remains unknown whether these
abnormalities are a direct consequence of mitochondrial
dysfunction at the end plate or merely reflect NMJ damage
from the neuropathy and myopathy commonly found in
these patients.11,12
To address these questions, we present a large systematic
study of NMJ function in a cohort of patients with genetically
proven mitochondrial disease. This work provides evidence
that NMJ dysfunction is independent of coexisting neurop-
athy and myopathy, raising the possibility that the NMJ may
be specifically vulnerable to mitochondrial dysfunction.
Methods
Eighty participants (mean age 49.5 years, range 18–81 years,
29.8% males) with a confirmed genetic diagnosis of mito-
chondrial disease were recruited from a specialized mito-
chondrial disease clinic held in the Highly Specialised Rare
Mitochondrial Disorders of Adults and Children Service,
Newcastle Hospitals National Health Service Foundation
Trust. This is one of 3 nationally commissioned mitochon-
drial disease clinics in the United Kingdom. Referrals were
either based on a clinical suspicion of neuromuscular system
involvement or were performed as routine screening in ac-
cordance with the Newcastle Mitochondrial Disease Neu-
ropathy Guideline.13
Participants were assessed clinically using the Newcastle Mi-
tochondrial Disease Scale for Adults (NMDAS), a semi-
quantitative clinical rating scale designed for all forms of
mitochondrial disease.14 Each subsection was scored between
0 and 5 and included assessments of exercise tolerance, gait,
ptosis, external ophthalmoplegia, proximal weakness, and deep
tendon reflexes. Blood was also taken for creatine kinase (CK)
level and glycosylated hemoglobin (HbA1c).
All neurophysiology studies were performed and reviewed
by a consultant neurophysiologist (R.G.W.). Nerve con-
duction studies were performed using surface electrodes
(Natus Medical) on a Keypoint electromyography (EMG)
machine (Dantec). For motor studies, the median, ulnar,
common peroneal, and tibial nerves were studied; for sen-
sory studies, the median, ulnar, sural, and superficial pero-
neal nerves were assessed. Results were compared with
published reference data and classified as normal, motor-
sensory axonal polyneuropathy, sensory axonal neuropathy,
sensory neuronopathy, and motor-sensory demyelinating
neuropathy.
EMG was performed using a 25-G concentric needle (Natus
Medical) on the muscle(s) studied in single-fiber electro-
myography (SFEMG): extensor digitorum communis
(EDC) and/or orbicularis oculi (OO). In addition, EMGwas
performed on at least 2 othermuscles (deltoid, biceps brachii,
vastus lateralis, and tibialis anterior). Analysis of spontaneous
activity at rest, individual motor unit potentials, and of in-
terference pattern was made, and the results classified as
normal, neurogenic, or myopathic.
Repetitive nerve stimulation was performed in the first 33
participants (42.3%) and was normal in all. Patients found
this to be very uncomfortable, and for this reason, we limited
the examination to themore sensitive single-fiber EMG in the
remaining participants.
SFEMG was performed on the EDC and/or OO muscles
using a 25-G facial concentric needle (bandpass 1–10 kHz).
SFEMG was not possible in 2 patients because of severe
myoclonus or tremor. SFEMG was performed on the EDC
muscle in all of the remaining 78 patients and in the OO
muscle in 15 patients. The proportion of pairs with increased
jitter and/or blocking fibers was recorded, and the study was
considered abnormal when ≥10% of fiber pairs showed in-
creased jitter or blocking.15
Statistical analysis was performed using IBM SPSS Statistics
V24. Parametric data were compared between groups using
the unpaired Student t test, and nonparametric data were
compared using the Chi statistic.
Standard protocol approvals, registrations,
and patient consents
The study was approved by Newcastle and North Tyneside
Local Research Ethics Committee. All patients gave written
consent before study enrollment.
Data availability
Anonymized study data will be made available on request.
Results
Cohort characteristics
The most common specific genotypes were the m.3243A>G
pathogenic variant (30.6% of patients), followed by single,
large-scale mitochondrial DNA (mtDNA) rearrangements
(13.9%) and then pathogenic variants in mendelian-
inherited mitochondrial genes encoding proteins involved
in mtDNA maintenance: twinkle (11.1%), OPA1 (9.7%),
polymerase gamma (8.3%), and RRM2B (6.9%). The
remaining rarer genotypes each comprised fewer than 5% of
the total cohort (table).
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Table Clinical and electrophysiologic characteristics of the patient cohort
Age (y)/sex Genotype Phenotype NCS EMG % Jitter % Block Notes
73, F m.3243A>G MIDD S Ax Myo 15 0
52, M m.3243A>G MELAS N N 5 0
52, F m.3243A>G Asymptomatic N N 0 0
61, M m.3243A>G MIDD M Ax Neuro 5 0
43, F m.3243A>G Ataxia and Crohn
disease
N Myo 10 5
44, M m.3243A>G Myalgia and epilepsy N N 0 0
54, F m.3243A>G MIDD CTS N 0 0
62, F m.3243A>G CPEO and DM S Ax N 0 0
51, M m.3243A>G CPEO and ptosis M Ax N 0 0
47, M m.3243A>G MIDD M Ax Neuro 0 0
26, M m.3243A>G MELAS S Ax Myo 0 0
71, F m.3243A>G CPEO S Ax Myo 0 0
55, F m.3243A>G MIDD N N 0 0
30, M m.3243A>G MIDD N N 7.7 0
53, F m.3243A>G MIDD CTS N 0 0
38, F m.3243A>G MIDD N N 0 0
53, M m.3243A>G MIDD N N 0 0
49, M m.3243A>G MIDD N N 0 0
58, F m.3243A>G MIDD N N 9.5 0
44, F m.3243A>G MIDD N N 0 0
22, F m.3243A>G MIDD N Myo 0 0
61, F m.3243A>G DM and epilepsy N N 0 0
67, M mtDNA deletion CPEO N N 20 0 MG, AChE
70, M mtDNA deletion CPEO and ptosis M Ax Myo 11.5 7.7 MG, AChE
36, F mtDNA deletion CPEO N Myo 25 5
54, F mtDNA deletion KSS N N 5 5
32, F mtDNA deletion CPEO and ptosis N Myo 0 0
22, M mtDNA deletion CPEO and ptosis N Myo 0 0
50, F mtDNA deletion CPEO N Myo 0 0
67, F mtDNA deletion Proximal weakness
and ptosis
N Myo 4.6 4.6
41, F mtDNA deletion CPEO and ptosis N Myo 0 0 MG, AChE
50, M mtDNA deletion CPEO, ptosis, and epilepsy M Dem N 0 0
27, M mtDNA deletion CPEO N Myo 0 0
48, M mtDNA deletion CPEO and ptosis N N 0 0
67, F mtDNA deletion CPEO and proximal weakness N Myo 4.8 0
47, F TWNK (ad) Ptosis N N 40 0
49, F TWNK (ad) CPEO N N 40 0
Continued
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Table Clinical and electrophysiologic characteristics of the patient cohort (continued)
Age (y)/sex Genotype Phenotype NCS EMG % Jitter % Block Notes
60, F TWNK (ad) CPEO and ptosis N Myo 20 10
35, F TWNK (ad) CPEO N N 0 0
54, F TWNK (ad) Ptosis N Myo 0 0
57, F TWNK (ad) Ptosis N Myo 0 0
77, F TWNK (ad) CPEO N Myo 5 0
72, F TWNK (ad) Proximal weakness N Myo 4.4 4.4
64, F TWNK (ad) CPEO N Myo 13.6 13.6
44, F OPA1 (ad) OA S Ax Myo 17.4 4.4
34, M OPA1 (ad) OA, proximal weakness,
and ataxia
N N 0 0
21, F OPA1 (ad) OA and proximal weakness N Myo 0 0
38, F OPA1 (ad) OA N N 0 0
42, F OPA1 (ad) OA S Ax Myo 15 5
46, M OPA1 (ad) OA, CPEO, and ptosis S Ax N 0 0
36, F OPA1 (ad) Asymptomatic N N 0 0
55, F POLG (ar) CPEO M Ax Neuro 5 0
64, F POLG (ar) CPEO and ptosis S Ax Myo 20 0 OO
50, F POLG (ar) CPEO and ptosis N Myo 0 0
49, F POLG (ar) CPEO N N 0 0
25, F POLG (ar) Ataxia S Ax N 0 0
49, M Multiple mtDNA deletions CPEO and ptosis N Myo 0 0 MG, AChE
75, M RRM2B (ad) CPEO N Myo 35 0
49, F RRM2B (ad) Ptosis S Ax Myo 10 10
64, F RRM2B (ad) Ptosis N Myo 16 12
72, F RRM2B (ad) Ptosis N Myo 5 0
64, F RRM2B (ad) Ptosis N Myo 0 0
28, F RRM2B (ar) CPEO, deafness, and
proximal and respiratory
muscle weakness
M Dem Myo 0 0
49, M m.8344A>G MERRF M Ax Myo 30 0
54, F m.8344A>G Asymptomatic N Myo 35 5
47, F m.8344A>G Myalgia and fatigue N Myo 0 0
32, F m.8344A>G MERRF S Ax Myo N/A N/A a
41, F m.8344A>G Fatigue N Myo 0 0
28, M GFER (ar) Proximal weakness N Myo 0 0
18, M GFER (ar) Proximal weakness N Myo 0 0
65, F TOP3A (ar) CPEO and ptosis N N 0 0
62, F DNM2 (ad) CPEO and ptosis N N 0 0
29, F m.3365T>C (MT-ND1) Exercise intolerance
and lactic acidosis
N N 0 0
Continued
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The most common clinical manifestations attributable to mi-
tochondrial disease were progressive external ophthalmoplegia
and ptosis (59% of patients), muscle weakness (52.6%), ataxia
(38.5%), prominent fatigue/myalgia (37.2%), sensorineural
hearing loss (30.8%), diabetes mellitus (24.4%), and cardio-
myopathy (17.9%). Most participants exhibited a composite
phenotype of multiple symptoms and signs.
Prevalence of NMJ abnormalities
SFEMG was not possible in 2 participants because of severe
myoclonus or tremor. Twenty of 78 of the remaining par-
ticipants (25.6%) had evidence of NMJ dysfunction. The
highest prevalence of NMJ abnormalities was found in
patients with pathogenic RRM2B variants (3 of 6 = 50%),
followed by TWNK (4 of 9 = 33.3%), m.8344A>G (2 of 5 =
40%), OPA1 (2 of 7 = 28.6%), single, large-scale mtDNA
rearrangements (3 of 13 = 23%), POLG (1 of 6 = 16.7%),
and m.3243A>G (2 of 22 = 9.1%). The remaining genotypes
comprised fewer than 5 subjects each, making estimation of
the prevalence of NMJ dysfunction unreliable.
The highest percentage of both jittering and blocking fiber pairs
was found inparticipantswith theTwinklemutation (up to 40%
and 13.6%, respectively). No association was found between
severity of jitter or blocking and overall disease severity assessed
using the NMDAS scale, CK, or HbA1c level.
Correlation with coexisting
neuromuscular disorders
Neurophysiologic evidence of neuropathy was detected in 18
of 78 participants (23%); in 11 of these, only sensory fibers
were involved; in 6, a mixed motor and sensory axonal neu-
ropathy was found; and in 1 patient, a mixed demyelinating
neuropathy was found. Two participants had evidence of
carpal tunnel syndrome but not of a polyneuropathy. My-
opathy was found in 41 of 78 participants (52.6%). Ten
participants had both neuropathy and myopathy; in 8 of
these, the neuropathy affected sensory fibers only.
Treating neuropathy, myopathy, and NMJ dysfunction as
independent conditions, we compared the frequency of
neuropathy and myopathy in participants with and without
NMJ dysfunction. The frequency of neuropathy was similar
in participants with and without NMJ dysfunction (Chi sta-
tistic 0.97 p = 0.325). Furthermore, no participants with
neuropathy alone had evidence of NMJ dysfunction. In
contrast, the frequency of myopathy differed significantly
between groups, being higher in the group with NMJ dys-
function (Chi statistic 7.16, p = 0.0074). NMJ dysfunction
was also found in 9 patients with myopathy alone.
We found no difference in the overall NMDAS score, exercise
tolerance, gait, ptosis, external ophthalmoplegia, CK level, or
HbA1c level between participants with and without NMJ
dysfunction.
Three of the 20 participants (15%) with NMJ abnormality
had no neurophysiologic evidence of either neuropathy or
myopathy (1 patient with a single, large-scale mtDNA
Table Clinical and electrophysiologic characteristics of the patient cohort (continued)
Age (y)/sex Genotype Phenotype NCS EMG % Jitter % Block Notes
26, F m.14709T>C (MT-TE) Proximal and
distal weakness
N Myo 20 0
67, F m.12320A>G (MT-TL2) Proximal weakness N Myo 10 0
50, F m.5650G>A (MT-TA) Proximal weakness S Ax Myo 0 0
49, F m.1624C>T (MT-TV) Fatigue and cardiomyopathy N N 0 0
49, F m.15699A>G (MT-CYB) MELAS N Myo 0 0
43, M m.12271T>C (MT-TL2) CPEO and fatigue N Myo 10 0
81, F SDHA (ad) OA and fatigue N N N/A N/A a
Abbreviations: AChE = acetylcholine esterase therapy; ad = autosomal dominant; ar = autosomal recessive; CPEO = chronic progressive external
ophthalmoplegia; DM = diabetes mellitus; EMG = electromyography; KSS = Kearns-Sayre syndrome; M Ax = mixed axonal neuropathy; M Dem = mixed
demyelinating neuropathy; MELAS = mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; MERRF = myoclonic epilepsy with ragged red
fibers; MG =myasthenia gravis; MIDD =maternally inherited deafness and diabetes; mtDNA = deletion, single large-scalemitochondrial DNA rearrangement;
Myo = myopathic change on electromyography; N = normal; NCS = nerve conduction study; Neuro = neurogenic change on electromyography; OA = optic
atrophy; OO = abnormal jitter found only in orbicularis oculi; S Ax = sensory axonal neuropathy; SFEMG = single-fiber electromyography.
a SFEMG not possible due to myoclonus or tremor.
Treating neuropathy, myopathy, and
NMJ dysfunction as independent
conditions, we compared the
frequency of neuropathy and
myopathy in participants with and
without NMJ dysfunction.
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rearrangement and 2 patients with dominant TWNK var-
iants). The mean percentage of abnormal fiber pairs in par-
ticipants with neither myopathy nor neuropathy was higher
than in participants with myopathy alone or both myopathy
and neuropathy (33.3% in participants with neither vs 20.5%
myopathy alone vs 17.0% in both).
Discussion
We present a large systematic study of NMJ function in
a cohort of patients with genetically proven mitochondrial
disease. We find that 20 of 78 (25.6%) participants included
in the study population had abnormal NMJ transmission,
with jitter values similar to patients with myasthenia gravis.
NMJ abnormalities were seen in a wide range of mitochon-
drial genetic defects including nuclear gene defects, single
large-scale mtDNA rearrangements, and mtDNA point
mutations.
Our cohort was recruited from one of 3 national referral
clinics for mitochondrial disease, and all had genetically
proven mitochondrial disease. The spread of genotypes is
broadly similar to published population-based studies in that
the pathogenic m.3243A>G variant and single, large-scale
mtDNA deletions represent the 2 most common mito-
chondrial genotypes presenting with multisystem disease.16
However, our cohort was referred for neurophysiologic
testing based on a clinical suspicion of coexisting neuro-
muscular disease. Consequently, it is likely that the preva-
lence of NMJ dysfunction in our cohort overestimates that in
all patients with mitochondrial disease, which include
a considerable number of asymptomatic carriers. However,
to perform such detailed and time-consuming neurophysi-
ologic testing in asymptomatic carriers presents significant
logistical and ethical barriers.
Mitochondria are abundant in both the presynaptic motor
nerve terminals and the postsynaptic junctional folds.17
Given the key role of mitochondria in vesicle release and
recycling,18 it is perhaps surprising that we find no associa-
tion between the presence of neuropathy and NMJ dys-
function. This may be because the majority of patients had
a pure sensory neuropathy, which would not be expected to
affect the NMJ. In contrast, we find a strong association
between NMJ dysfunction and the presence of myopathy
across all genotypes. This may be coincidental, given that
both NMJ dysfunction and myopathy are common features
in mitochondrial disease. However, abnormal jitter and
blocking is described in several myopathies, including
myotonic dystrophy type 1,19 polymyositis,20 and inclusion
body myositis.21 The mechanism remains unclear, although
destruction of the postsynaptic folds has been described in
a rodent model of Duchennemuscular dystrophy.22Whether
similar changes occur in mitochondrial disease is unknown,
and to our knowledge, no ultrastructural studies of NMJ
morphology in mitochondrial disease have been performed.
Arguing against a causal relationship is the observation that in
15% of patients with NMJ dysfunction, no evidence was
found of either myopathy or neuropathy. Of interest, the
percentage of fibers with increased jitter was higher in this
group than in those with myopathy alone or both myopathy
and neuropathy. These patients with a primary defect of
neuromuscular transmission in what are presumably struc-
turally normal NMJs may be a particularly suitable group to
target with therapies that boost NMJ transmission.
Unfortunately, we found no simple means of identifying
these patients before neurophysiologic testing. Patients
with significant NMJ dysfunction did not differ in their
disease severity as assessed using the NMDAS scale or in
any of the relevant subsections. There was also no differ-
ence on routine blood tests (CK and HbA1c level). The
only predictor of NMJ dysfunction was electromyographic
evidence of myopathy; however, relying on this alone
would fail to identify those patients with a “pure” NMJ
disorder. This means that at present, the only means of
reliably detecting NMJ dysfunction is with detailed neu-
rophysiology including single-fiber EMG. The time taken
to perform this technique, the need for specialist expertise,
and the limited availability in some countries limit the
applicability of these findings. Nevertheless, a case can be
made that patients being seen in a specialist center in
which these are available should be considered for SFEMG
at least once.
The distinction between genetically proven mitochondrial
disease and autoimmune myasthenia gravis (particularly
ocular myasthenia) is not always obvious on clinical grounds
alone, and our data show that SFEMG abnormalities can be
seen in both patient populations. Patients with autoimmune
myasthenia gravis typically show marked fluctuation in
symptom severity, often have bulbar symptoms early in the
disease, and an association with other autoimmune dis-
eases.23 In contrast, patients with mitochondrial disease
typically have limited symptom fluctuation, develop bulbar
symptoms late on, and have a pattern of multisystem disease
including other neurologic symptoms such as seizures and
ataxia.24 Autoantibody testing (including antibodies to the
acetylcholine receptor, muscle specific kinase, LRP4, and
agrin) can help confirm an autoimmune etiology, but up to
15% of patients are seronegative for known autoantibodies.
Arguing against a causal relationship
is the observation that in 15% of
patients with NMJ dysfunction, no
evidence was found of either
myopathy or neuropathy.
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Perhaps the most important point is that mitochondrial
disease should be considered in patients with suspected
autoimmune myasthenia gravis who fail to respond to
immunosuppression.
Acknowledgment
Work in our laboratory is supported by the Wellcome
Centre for Mitochondrial Research (203105/Z/16/Z), the
Medical Research Council (MRC) Centre for Translational
Research in Neuromuscular Disease, Mitochondrial Disease
Patient Cohort (UK) (G0800674), the Lily Foundation, the
UK NIHR Biomedical Research Centre for Ageing and Age-
related disease award to the Newcastle upon Tyne
Foundation Hospitals NHS Trust, the MRC/EPSRC
Molecular Pathology Node, and the UK NHS Highly
Specialised Service for Rare Mitochondrial Disorders of
Adults and Children. YSN holds an NIHR Clinical Lecture-
ship in Neurology (CL-2016-01-003).
Study funding
No targeted funding reported.
Disclosure
The authors report no disclosures relevant to the manu-
script. Full disclosure form information provided by the
authors is available with the full text of this article at
Neurology.org/cp.
Publication history
Received byNeurology: Clinical Practice April 25, 2019. Accepted in final
form November 18, 2019.
References
1. GormanGS, Elson JL, Newman J, et al. Perceived fatigue is highly prevalent and debilitating
in patients with mitochondrial disease. Neuromuscul Disord 2015;25:563–566.
2. Mancuso M, Angelini C, Bertini E, et al. Fatigue and exercise intolerance in mito-
chondrial diseases. Literature revision and experience of the Italian Network of mi-
tochondrial diseases. Neuromuscul Disord 2012;22(suppl 3):S226–S229.
3. Taylor RW, Turnbull DM. Mitochondrial DNAmutations in human disease. Nat Rev
Genet 2005;6:389–402.
4. Zwarts MJ, Bleijenberg G, van Engelen BG. Clinical neurophysiology of fatigue. Clin
Neurophysiol 2008;119:2–10.
5. Whittaker RG, Schaefer AM, Taylor RW, Turnbull DM.Differential diagnosis in ptosis and
ophthalmoplegia: mitochondrial disease or myasthenia?. J Neurol 2007;254:1138–1139.
6. Finsterer J, Oberman I, Reitner A. Respiratory chain complex-I defect mimicking
myasthenia. Metab Brain Dis 2002;17:41–46.
7. Ben Yaou R, Laforet P, Becane HM, et al. Misdiagnosis of mitochondrial myopathies:
a study of 12 thymectomized patients. Revue Neurologique 2006;162:339–346.
8. Fawcett PR, Mastaglia FL, Mechler F. Electrophysiological findings including single
fibre EMG in a family with mitochondrial myopathy. J Neurol Sci 1982;53:397–410.
9. Girlanda P, Toscano A, Nicolosi C, et al. Electrophysiological study of neuromuscular
system involvement in mitochondrial cytopathy. Clin Neurophysiol 1999;110:
1284–1289.
TAKE-HOME POINTS
NMJ abnormalities are common in mitochondrial
disease.
Abnormalities can occur in the absence of coexisting
neuropathy or myopathy, suggesting specific in-
volvement of the NMJ in mitochondrial disease.
Whether modulators of neuromuscular transmis-
sion have a role in treating these patients is worthy
of further study.
Appendix Authors
Name Location Role Contribution
Luis P. Braz, MD Department of
Neurology,
Centro Hospitalar
Universita´rio de
São João, Porto,
Portugal
Author Drafting
a significant portion
of the manuscript
Appendix (continued)
Name Location Role Contribution
Yi Shiau Ng, PhD,
MRCP
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Major role in the
acquisition of data
Gra´inne S.
Gorman, PhD,
FRCP
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Major role in the
acquisition of data
Andrew M.
Schaefer, MRCP
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Major role in the
acquisition of data
Robert
McFarland, PhD,
MRCPCH, MRCP
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Major role in the
acquisition of data
Robert W. Taylor,
PhD, FRCPath
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Major role in the
acquisition of data
and analyzed the
data
DougM. Turnbull,
PhD, FRCP
Wellcome Centre for
Mitochondrial
Research, Translational
and Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Designed and
conceptualized the
study
Roger Whittaker,
PhD, FRCP
Translational and
Clinical Research
Institute, Newcastle
University, Newcastle
upon Tyne, UK
Author Designed and
conceptualized the
study, analyzed the
data, and drafted
the manuscript for
intellectual content
Neurology.org/CP Neurology: Clinical Practice | Volume , Number  | Month 2019 7
10. Cruz-Martinez A, Arpa J, Santiago S, et al. Single fiber electromyography (SFEMG)
in mitochondrial diseases (MD). Electromyogr Clinical Neurophysiol 2004;44:
35–38.
11. Lax NZ, Whittaker RG, Hepplewhite PD, et al. Sensory neuronopathy in patients
harbouring recessive polymerase γ mutations. Brain 2012;135(pt 1):62–71.
12. Whittaker RG, Hall E, Mansoor MK, Taylor RW, Turnbull DM. Incidence of carpal
tunnel syndrome in adult patients with mitochondrial disease. J Peripher Nerv Syst
2013;18:59–61.
13. Available at: newcastle-mitochondria.com/clinical-professional-home-page/clinical-
publications/clinical-guidelines/. Accessed April 2019.
14. Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mi-
tochondrial disease in adults: a scale to monitor progression and treatment. Neu-
rology 2006;66:1932–1934.
15. Jablecki CK. AAEM case report #3: myasthenia gravis. Muscle Nerve 1991;14:
391–397.
16. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA
disease in adults. Ann Neurol 2008;63:35–39.
17. Rygiel KA, Picard M, Turnbull DM. The ageing neuromuscular system
and sarcopenia: a mitochondrial perspective. J Physiol (Lond) 2016;594:4499–4512.
18. Pathak D, Shields LY, Mendelsohn BA, et al. The role of mitochondrially derived ATP
in synaptic vesicle recycling. J Biol Chem 2015;290:22325–22336.
19. Kuntzer T. Electrophysiological testing in muscle channelopathies. Revue Neuro-
logique 2004;160(5 pt 2):S49–S54.
20. Pestronk A, Drachman DB. Antibody-mediated membrane abnormalities in poly-
myositis: reduction of acetylcholine receptors by immunoglobulin. Ann N Y Acad Sci
1987;505:357–367.
21. Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis.
Muscle Nerve 1990;13:949–951.
22. Pratt SJP, Shah SB, Ward CW, Inacio MP, Stains JP, Lovering RM. Effects of in vivo
injury on the neuromuscular junction in healthy and dystrophic muscles. J Physiol
(Lond) 2013;591:559–570.
23. Gilhus NE. Myasthenia gravis. NEJM. 2016;375:2570–2581.
24. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis
Primers 2016;2:16080.
8 Neurology: Clinical Practice | Volume , Number  | Month 2019 Neurology.org/CP
DOI 10.1212/CPJ.0000000000000795
 published online December 26, 2019Neurol Clin Pract 
Luis P. Braz, Yi Shiau Ng, Gráinne S. Gorman, et al. 
cohort study
Neuromuscular junction abnormalities in mitochondrial disease: An observational
This information is current as of December 26, 2019
Services
Updated Information &
 95.full.html
http://cp.neurology.org/content/early/2019/12/26/CPJ.00000000000007
including high resolution figures, can be found at:
Subspecialty Collections
 netics-mitochondrial_disorders
http://cp.neurology.org//cgi/collection/mitochondrial_disorders_see_ge
Mitochondrial disorders; see Genetics/Mitochondrial disorders
 http://cp.neurology.org//cgi/collection/emg
EMG
 http://cp.neurology.org//cgi/collection/all_neuromuscular_disease
All Neuromuscular Disease
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://cp.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://cp.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
since 2011, it is now a bimonthly with 6 issues per year. Copyright Copyright © 2019 The Author(s). 
is an official journal of the American Academy of Neurology. Published continuouslyNeurol Clin Pract 
